Campbell & CO Investment Adviser LLC Takes Position in Progyny, Inc. $PGNY

Campbell & CO Investment Adviser LLC bought a new stake in Progyny, Inc. (NASDAQ:PGNY) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,648 shares of the company’s stock, valued at approximately $487,000.

A number of other institutional investors have also recently bought and sold shares of the business. Ameriprise Financial Inc. raised its stake in shares of Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after buying an additional 545,431 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new stake in shares of Progyny during the 2nd quarter valued at about $10,525,000. Nomura Holdings Inc. bought a new stake in Progyny in the second quarter valued at about $9,368,000. Fort Washington Investment Advisors Inc. OH raised its position in Progyny by 33.1% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,656,558 shares of the company’s stock worth $35,649,000 after purchasing an additional 412,395 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new position in Progyny during the second quarter worth about $4,670,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Price Performance

PGNY stock opened at $25.00 on Friday. The business has a fifty day moving average price of $25.78 and a 200 day moving average price of $23.28. Progyny, Inc. has a fifty-two week low of $17.98 and a fifty-two week high of $28.75. The stock has a market capitalization of $2.16 billion, a price-to-earnings ratio of 39.68, a P/E/G ratio of 1.61 and a beta of 0.93.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, November 6th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.39 by $0.06. The company had revenue of $313.35 million for the quarter, compared to analysts’ expectations of $299.23 million. Progyny had a return on equity of 10.71% and a net margin of 4.46%.The business’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.11 earnings per share. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. On average, equities analysts expect that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several analyst reports. Canaccord Genuity Group upped their price objective on Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research note on Monday, November 17th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 1st. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. Finally, Citizens Jmp upgraded shares of Progyny from a “market perform” rating to an “outperform” rating and set a $30.00 target price on the stock in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $29.36.

Insider Buying and Selling

In related news, CEO Peter Anevski acquired 79,500 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was purchased at an average price of $24.29 per share, for a total transaction of $1,931,055.00. Following the transaction, the chief executive officer directly owned 680,251 shares of the company’s stock, valued at approximately $16,523,296.79. This trade represents a 13.23% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Mark S. Livingston sold 21,303 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $25.50, for a total value of $543,226.50. Following the completion of the transaction, the chief financial officer owned 48,358 shares in the company, valued at $1,233,129. The trade was a 30.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 22,046 shares of company stock valued at $561,691. 9.40% of the stock is currently owned by company insiders.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.